ViroStatics, srl - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

ViroStatics, srl - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'ViroStatics, srl - Product Pipeline Review - 2014', provides an overview of the ViroStatics, srl's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ViroStatics, srl's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of ViroStatics, srl including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of ViroStatics, srl's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the ViroStatics, srl's pipeline products

Reasons to buy

- Evaluate ViroStatics, srl's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of ViroStatics, srl in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the ViroStatics, srl's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of ViroStatics, srl and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of ViroStatics, srl
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of ViroStatics, srl and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
ViroStatics, srl Snapshot 7
ViroStatics, srl Overview 7
Key Information 7
Key Facts 7
ViroStatics, srl - Research and Development Overview 8
Key Therapeutic Areas 8
ViroStatics, srl - Pipeline Review 12
Pipeline Products by Stage of Development 12
Pipeline Products - Monotherapy 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
ViroStatics, srl - Pipeline Products Glance 16
ViroStatics, srl - Early Stage Pipeline Products 16
Discovery Products/Combination Treatment Modalities 16
ViroStatics, srl - Drug Profiles 18
Small Molecule to Inhibit CDK9 for EBV and HSV Infections 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecule to Inhibit CDK9 for Oncology 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecule to Inhibit CDK9 for Rheumatoid Arthritis 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
VS-1002 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
VS-1003 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
VS-1004 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
VS-1005 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
VS-1006 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
VS-1007 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
VS-1008 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
VS-1010 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
VS-1011 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
VS-1013 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
VS-1014 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VS-1016 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VS-1017 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VS-1018 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
VS-1019 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
VS-1020 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
VS-1021 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
VS-1022 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
VS-1023 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
VS-1024 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
VS-1025 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
VS-1026 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
VS-1027 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
VS-1028 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
VS-1032 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
VS-1033 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
VS-1034 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
VS-1035 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
VS-1036 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
VS-lOI l 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
VSl-001 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
VSl-010 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
ViroStatics, srl - Pipeline Analysis 69
ViroStatics, srl - Pipeline Products by Target 69
ViroStatics, srl - Pipeline Products by Molecule Type 70
ViroStatics, srl - Pipeline Products by Mechanism of Action 71
ViroStatics, srl - Dormant Projects 72
ViroStatics, srl - Locations And Subsidiaries 73
Head Office 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 75
Disclaimer 75

List of Tables
ViroStatics, srl, Key Information 7
ViroStatics, srl, Key Facts 7
ViroStatics, srl - Pipeline by Indication, 2014 10
ViroStatics, srl - Pipeline by Stage of Development, 2014 12
ViroStatics, srl - Monotherapy Products in Pipeline, 2014 13
ViroStatics, srl - Partnered Products in Pipeline, 2014 14
ViroStatics, srl - Partnered Products/ Combination Treatment Modalities, 2014 15
ViroStatics, srl - Discovery, 2014 16
ViroStatics, srl - Pipeline by Target, 2014 69
ViroStatics, srl - Pipeline by Molecule Type, 2014 70
ViroStatics, srl - Pipeline Products by Mechanism of Action, 2014 71
ViroStatics, srl - Dormant Developmental Projects,2014 72